Advances in pharmacology最新文献

筛选
英文 中文
Toward non-invasive CNS delivery: The emergence of brain shuttle peptides. 迈向无创中枢神经传递:脑穿梭肽的出现。
Advances in pharmacology Pub Date : 2026-01-01 Epub Date: 2026-04-28 DOI: 10.1016/bs.apha.2026.03.001
Macarena Sánchez-Navarro, Benjamí Oller-Salvia
{"title":"Toward non-invasive CNS delivery: The emergence of brain shuttle peptides.","authors":"Macarena Sánchez-Navarro, Benjamí Oller-Salvia","doi":"10.1016/bs.apha.2026.03.001","DOIUrl":"10.1016/bs.apha.2026.03.001","url":null,"abstract":"<p><p>The blood-brain barrier (BBB) is a highly specialized interface that preserves neural homeostasis but severely limits the entry of therapeutic agents, posing a major challenge for central nervous system (CNS) drug development. While invasive approaches such as intracerebral injection and focused ultrasound can transiently bypass the barrier, their complexity and safety concerns restrict clinical applicability, particularly in chronic conditions. Non-invasive strategies that exploit endogenous transport mechanisms-carrier-mediated uptake, adsorptive-mediated transcytosis (AMT), and receptor-mediated transcytosis (RMT)-may offer a safer solution. Within this framework, brain shuttles have emerged as molecular vectors designed to cooperate with endothelial biology rather than disrupt it. These include antibodies, proteins, small molecules, and peptides, each with distinct advantages and limitations. Among them, peptides stand out for their versatility, manufacturability, and chemical tunability. Advances in solid-phase synthesis, non-natural modifications, and rational design have enabled peptides to achieve a balance between uptake efficiency and release beyond the endothelium. Their modular nature supports conjugation to diverse payloads, including small molecules, proteins, nucleic acids, and nanoparticles, while maintaining functional integrity. Peptide shuttles also offer broader receptor targeting and compatibility with multiple administration routes, positioning them as a cornerstone of future CNS delivery platforms. This chapter provides a mechanistic overview of the BBB, reviews invasive and non-invasive delivery strategies, and introduces the concept and evolution of brain shuttle peptides. It sets the stage for subsequent discussions on discovery methodologies, chemical optimization, validation models, and translational pathways, highlighting the promise of peptide-enabled systems to transform therapeutic access to the brain.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"105 ","pages":"1-39"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148196922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brain shuttle peptides derived from natural proteins. 脑穿梭肽来源于天然蛋白质。
Advances in pharmacology Pub Date : 2026-01-01 Epub Date: 2026-02-20 DOI: 10.1016/bs.apha.2026.01.002
Andrej Nikolić, Toni Todorovski
{"title":"Brain shuttle peptides derived from natural proteins.","authors":"Andrej Nikolić, Toni Todorovski","doi":"10.1016/bs.apha.2026.01.002","DOIUrl":"10.1016/bs.apha.2026.01.002","url":null,"abstract":"<p><p>Blood-brain barrier (BBB) is the primary physiological barrier that regulates the movement of substances between the systemic circulation and the brain. Its unique structure, based on specialized endothelial cells, allows tight regulation of central nervous system (CNS) homeostasis and at the same time is the main hurdle in the modern medicine to treat neurological conditions. Many promising in vitro drugs become ineffective in vivo due to BBB restrictive permeability. However, in the last two decades, a variety of molecules, mainly peptide-based and named brain shuttle peptides, were able to ferry various payloads (small molecules, proteins, antibodies etc.) into the brain. Therefore, these shuttles could become key future therapeutics to fight various CNS conditions. Brain shuttle peptides are part of a larger family of cell-penetrating peptides (CPPs) that utilize different modes of membrane transport with predominance of adsorptive-mediated transcytosis (AMT) and receptor-mediated transcytosis (RMT). The discovery and development process of new brain shuttle peptides is mainly guided by using rational design and bioinformatics approaches focusing mostly on proteins from natural sources (viruses, amphibians, reptiles and mammals). In the last years, the virus- and mammal-derived brain shuttle peptides have been gaining increased attention due to their superb translocation capacity, low immunogenicity and toxicity, good stability and ease of preparation. Here, we will focus on the most prominent brain shuttle peptides of viral and animal origin with documented BBB crossing capabilities, discussing their mechanisms of translocation and therapeutic applications. Notably, the two brain shuttle peptides that have successfully progressed to clinical trials thus far originate from a viral source (TAT) and a mammalian source (Angiopep-2).</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"105 ","pages":"41-82"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148196952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vitro blood-brain barrier models for the study of brain shuttle peptide transport. 体外血脑屏障模型研究脑穿梭肽运输。
Advances in pharmacology Pub Date : 2026-01-01 Epub Date: 2026-02-25 DOI: 10.1016/bs.apha.2026.01.003
Ana Martins, Ana Raquel Santa-Maria, Nóra Kucsápszky, Luíza Santa Brígida de Barros Góes, Kinga Molnár, Sheila Sousa Gomes Fortes, Emanuel Carrilho, Maria A Deli, Fruzsina R Walter
{"title":"In vitro blood-brain barrier models for the study of brain shuttle peptide transport.","authors":"Ana Martins, Ana Raquel Santa-Maria, Nóra Kucsápszky, Luíza Santa Brígida de Barros Góes, Kinga Molnár, Sheila Sousa Gomes Fortes, Emanuel Carrilho, Maria A Deli, Fruzsina R Walter","doi":"10.1016/bs.apha.2026.01.003","DOIUrl":"10.1016/bs.apha.2026.01.003","url":null,"abstract":"<p><p>Brain shuttles, such as antibody fragments, bispecific antibodies, peptides, or nanocarriers, are engineered to exploit the blood-brain barrier (BBB) transport mechanisms to deliver therapeutics to the brain. This strategy has emerged as a potential game-changer to overcome the therapeutic challenge of many brain diseases: the hindered passage of molecules across the BBB. Due to special tight junctions, low intracellular vesicles, negatively charged glycocalyx, and highly regulated transport, brain endothelial cells limit central nervous system drug delivery. To facilitate drug passage to the brain, brain shuttles utilize endogenous transport pathways, such as receptor-mediated and adsorptive-mediated transcytosis. In vitro BBB models provide a controlled environment to evaluate the passage of brain shuttles across the BBB. Here, we present the cellular and methodological basis for selecting an appropriate model type for any shuttle study, with relevant barrier tightness and cellular composition. We explain how to apply rigorous experimental controls to assess transport efficiency, receptor specificity, cytotoxicity, and barrier integrity, which helps to identify specific transport phenomena, and exclude artefacts.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"105 ","pages":"365-413"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148196914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Manufacturing as biology: How T-cell processing shapes therapeutic outcomes. 作为生物学的制造:t细胞加工如何影响治疗结果。
Advances in pharmacology Pub Date : 2026-01-01 Epub Date: 2026-05-25 DOI: 10.1016/bs.apha.2026.05.005
Nikolai Przybylski, Qinghe Zeng, Xiao Huang
{"title":"Manufacturing as biology: How T-cell processing shapes therapeutic outcomes.","authors":"Nikolai Przybylski, Qinghe Zeng, Xiao Huang","doi":"10.1016/bs.apha.2026.05.005","DOIUrl":"10.1016/bs.apha.2026.05.005","url":null,"abstract":"<p><p>T-cell therapies have transformed the treatment landscape for hematologic malignancies and show growing promise for solid tumors and non-oncologic diseases. Unlike conventional drugs, these living therapeutics are shaped not only by genetic engineering but also by the ex vivo manufacturing process itself, which functions as a powerful biological determinant of cell fate and function. Here, we present a framework that conceptualizes manufacturing as a form of biological programming that governs therapeutic outcomes through its effects on T-cell phenotype, fitness, and functional durability. We review how each major processing step, including isolation, selection, activation, transduction, expansion, and formulation, influences the balance between cell quantity and quality, the two principal determinants of clinical efficacy. Particular emphasis is placed on how extracellular cues encountered during manufacturing, such as physical properties of activation materials, stimulatory ligand presentation, cytokine and nutrient composition, and gene delivery method, shape transcriptional, epigenetic, and metabolic programs that define cell phenotypes directly linked to cell quantity and quality. Emerging strategies to deliberately steer T-cell differentiation toward persistence-associated phenotypes, enhance metabolic fitness, and reduce vein-to-vein time are highlighted as critical avenues for next-generation manufacturing. Additionally, reducing inconsistency and cost remain areas of strategic importance to expand availability. Collectively, this review underscores that optimizing T-cell therapy requires treating manufacturing not as a logistical necessity but as a controllable biological intervention. A mechanistic understanding of how processing decisions program cellular behavior will enable the rational design of more potent, durable, and scalable T-cell products for diverse clinical applications.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"106 ","pages":"141-177"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148395581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Engineering T cell metabolism to enhance therapeutic efficacy. 改造T细胞代谢,提高治疗效果。
Advances in pharmacology Pub Date : 2026-01-01 Epub Date: 2026-05-26 DOI: 10.1016/bs.apha.2026.05.001
Laura Anderson, Nicola J Mason, Roddy S O'Connor
{"title":"Engineering T cell metabolism to enhance therapeutic efficacy.","authors":"Laura Anderson, Nicola J Mason, Roddy S O'Connor","doi":"10.1016/bs.apha.2026.05.001","DOIUrl":"https://doi.org/10.1016/bs.apha.2026.05.001","url":null,"abstract":"<p><p>Adoptive cell therapies, particularly chimeric antigen receptor (CAR) T cells, function as \"living drugs\" whose efficacy depends not only on target recognition but also on the metabolic state of the infused product. T cell metabolism governs energy production, redox homeostasis, biomass generation, and adaptation to persistent antigen exposure and nutrient stress, thereby shaping expansion, effector function, persistence, and susceptibility to exhaustion. Core metabolic programs relevant to these outcomes include glycolysis and mitochondrial respiration, anaplerosis and amino acid metabolism, lipid metabolism, and NAD- and redox-linked pathways. These programs help determine adoptive cell therapy-relevant phenotypes, including the balance between immediate cytotoxicity and long-term durability. Increasing evidence further suggests that metabolism can be therapeutically manipulated across the lifecycle of adoptive cell therapy through ex vivo manufacturing, receptor and signaling design, direct gene engineering, and post-infusion support. Collectively, these findings support a pharmacologic framework in which metabolic state is not merely a descriptive correlate of product quality, but a controllable determinant of therapeutic performance. A deeper mechanistic understanding of these pathways may enable more precise strategies to improve persistence, function, and long-term antitumor efficacy.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"106 ","pages":"117-139"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148395604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glp-1 receptor agonists in obesity: Current evidence and clinical outcomes. Glp-1受体激动剂治疗肥胖:目前的证据和临床结果
Advances in pharmacology Pub Date : 2026-01-01 Epub Date: 2026-09-08 DOI: 10.1016/bs.apha.2026.08.009
Josep Vidal
{"title":"Glp-1 receptor agonists in obesity: Current evidence and clinical outcomes.","authors":"Josep Vidal","doi":"10.1016/bs.apha.2026.08.009","DOIUrl":"https://doi.org/10.1016/bs.apha.2026.08.009","url":null,"abstract":"<p><p>The availability of pharmacological agents targeting gastrointestinal hormone receptors has transformed the clinical management of obesity in recent years. Several GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists have emerged as highly effective evidence-based therapeutic options for people living with obesity, offering benefits that extend well beyond body weight reduction alone. Based on the available efficacy and safety data, the U.S. Food and Drug Administration currently recognizes several indications for subcutaneous semaglutide, oral semaglutide, tirzepatide, and orforglipron in the management of people living with obesity. In selecting the right medicine for the right patient, the characteristics of the individual (sex, presence of type 2 diabetes), the goals of therapy (weight loss, control of besity-related comorbidities), and patient preferences (i.e. oral versus subcutaneous administration) should be considered. Available evidence clearly indicates that maintenance of the clinical benefits achieved with pharmacological treatment of obesity likely requires ongoing therapy. Addressing this challenge requires a better understanding of the barriers that limit long-term treatment adherence, as well as a clearer definition of therapeutic goals during the weight-maintenance phase.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"107 ","pages":"333-355"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Practical use of GLP-1-based medications in obesity clinics. 基于glp -1的药物在肥胖诊所的实际应用。
Advances in pharmacology Pub Date : 2026-01-01 Epub Date: 2026-09-21 DOI: 10.1016/bs.apha.2026.08.011
Priyanka D Jethwani, Rajiev Hallock, Marcio L Griebeler
{"title":"Practical use of GLP-1-based medications in obesity clinics.","authors":"Priyanka D Jethwani, Rajiev Hallock, Marcio L Griebeler","doi":"10.1016/bs.apha.2026.08.011","DOIUrl":"https://doi.org/10.1016/bs.apha.2026.08.011","url":null,"abstract":"<p><p>This chapter is a practical, clinic-oriented guide to the everyday use of GLP-1-based medications for obesity, written to support the decisions clinicians make from the first visit through long-term management. It focuses on the four agents FDA-approved for chronic weight management at the time of writing, liraglutide, subcutaneous and oral semaglutide, tirzepatide, and orforglipron. After briefly grounding the reader in the incretin-based mechanisms that account for these agents' efficacy and cardiometabolic benefits, the chapter concentrates on the tasks that occupy the obesity clinic: identifying appropriate candidates and using body mass index alongside measures of central adiposity; conducting a structured pretreatment evaluation to screen for contraindications and establish baseline monitoring parameters; recognizing and managing the class-wide and agent-specific adverse effects; and selecting an agent by matching its efficacy and comorbidity-specific indications to the individual patient. Detailed, individualized dose-titration strategies are provided to optimize tolerability while avoiding both over-aggressive escalation and treatment inertia, along with practical guidance on managing missed doses, concomitant medications, and treatment interruptions. The chapter closes by framing obesity as a chronic, relapsing disease: drawing on randomized withdrawal trials showing that weight loss and cardiometabolic gains largely reverse when treatment stops, it offers guidance on counseling patients, sustaining therapy through plateaus and coverage disruptions, and approaching tapering or discontinuation when it becomes necessary.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"107 ","pages":"71-95"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolution of obesity medicine: From historical perspectives to precision obesity medicine and healthy longevity. 肥胖医学的演变:从历史角度看精准肥胖医学与健康长寿。
Advances in pharmacology Pub Date : 2026-01-01 Epub Date: 2026-10-26 DOI: 10.1016/bs.apha.2026.09.002
Bartolomé Burguera
{"title":"Evolution of obesity medicine: From historical perspectives to precision obesity medicine and healthy longevity.","authors":"Bartolomé Burguera","doi":"10.1016/bs.apha.2026.09.002","DOIUrl":"https://doi.org/10.1016/bs.apha.2026.09.002","url":null,"abstract":"<p><p>Obesity is now recognized as a chronic, progressive, and relapsing multisystem disease rather than simply the result of excessive caloric intake, limited physical activity, and individual behavior. Its pathophysiology reflects interactions among genetic susceptibility, neuroendocrine regulation, adipose tissue function, environmental factors, and behavior. This evolving understanding has changed the clinical approach to obesity and contributed to the development of more effective treatments. The introduction of incretin-based pharmacotherapy, together with advances in metabolic surgery, has substantially increased the degree of weight loss that can be achieved and has demonstrated benefits across a broad range of obesity-related conditions. As a result, treatment goals have expanded beyond weight reduction to include the prevention and treatment of complications, improvement in metabolic health, and preservation of physical function and quality of life. Long-term treatment should be individualized according to disease severity, comorbidities, functional status, treatment response, and patient preferences. Despite these advances, access to effective obesity care remains limited, and sustainable models for long-term treatment are needed. Clinical phenotyping and biomarkers may improve treatment selection, while digital tools can support monitoring and continuity of care. The future of obesity medicine will depend on translating therapeutic advances into individualized, accessible, and sustained clinical care, with the ultimate goal of reducing morbidity and mortality while preserving health and physical function across the lifespan.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"107 ","pages":"1-18"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Physiological strategies for brain delivery. 脑输送的生理策略。
Advances in pharmacology Pub Date : 2026-01-01 Epub Date: 2026-03-19 DOI: 10.1016/bs.apha.2026.02.007
Daniel Gonzalez-Carter
{"title":"Physiological strategies for brain delivery.","authors":"Daniel Gonzalez-Carter","doi":"10.1016/bs.apha.2026.02.007","DOIUrl":"10.1016/bs.apha.2026.02.007","url":null,"abstract":"<p><p>The blood-brain barrier (BBB) remains an obstacle to treat neurological diseases, prompting the development of delivery strategies to target therapies to the brain. Receptor-mediated transport has become a major focus of research efforts aiming to exploit innate transport mechanisms. The last decade has seen important innovations ranging from ligand-modified nanocarriers to engineered biologics that harness trafficking pathways. However, such developments have demonstrated brain delivery requires a nuanced engagement of target proteins to ensure efficient internalization and intracellular trafficking. Therefore, much remains to be understood of BBB transport mechanisms to ensure maximal brain delivery of therapeutics. Furthermore, accumulating evidence indicates cell-membrane targets do not necessarily require an innate biological transport function to promote transport across the BBB. These observations open the possibility of expanding our target repertoire beyond transport-related proteins. Novel targets may therefore include structural or signalling proteins which have a more favourable brain-to-periphery expression ratio. In addition, they may include non-protein components of the cell membrane, for instance the glycocalyx covering endothelial surfaces. Such novel targets would therefore allow us to harness more fully the phenotypic specialization of brain endothelial cells. In addition, recent years have witnessed the development of targeting strategies harnessing not only structural differences of brain endothelial cells, but in addition take advantage of the dynamic control of BBB specialization. As such, advances have been made to exploit cell-membrane dynamics; haemodynamic response; vascular segmentation; or pathological modulation. The field of brain delivery is therefore advancing towards exploiting the highly unique physiology of the BBB to achieve a more dynamic approach to BBB targeting and maximize transport into the brain.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"105 ","pages":"415-456"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148196896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brain delivery of proteins with shuttle peptides. 用穿梭肽传递大脑中的蛋白质。
Advances in pharmacology Pub Date : 2026-01-01 Epub Date: 2026-02-24 DOI: 10.1016/bs.apha.2026.02.006
Alejandro Benítez-Troncoso, Macarena Sánchez-Navarro, Marina Plaza-Garrido
{"title":"Brain delivery of proteins with shuttle peptides.","authors":"Alejandro Benítez-Troncoso, Macarena Sánchez-Navarro, Marina Plaza-Garrido","doi":"10.1016/bs.apha.2026.02.006","DOIUrl":"10.1016/bs.apha.2026.02.006","url":null,"abstract":"<p><p>Therapeutic proteins have emerged as potential candidates for the management of neurodegenerative disorders affecting the central nervous system (CNS). However, their effective delivery to the CNS remains a major challenge, primarily due to the presence of the blood-brain barrier (BBB). To overcome this challenge, several brain-targeted delivery strategies based on peptides have been developed. These peptides harness endogenous BBB transport pathways to enhance the delivery of therapeutic proteins to the CNS. In order to develop new potential protein-based therapeutic candidates, considerable efforts have focused on engineering fusion proteins that combine therapeutic efficacy with enhanced BBB permeability.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"105 ","pages":"171-211"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148196916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书